DLA Piper advised Intercept Pharmaceuticals on the offering, and Davis Polk advised the sales agent involved.Intercept Pharmaceuticals, Inc. announced the SEC-registered at-the-market offering of its common…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
